Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis.
about
Sézary Syndrome and Atopic Dermatitis: Comparison of Immunological Aspects and TargetsAdvances in understanding and managing atopic dermatitisImmune Pathways in Atopic Dermatitis, and Definition of Biomarkers through Broad and Targeted TherapeuticsNew Developments in Biomarkers for Atopic DermatitisPsoriasis and Atopic Dermatitis.Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapyThe Changing Landscape of Alopecia Areata: The Therapeutic Paradigm.Target-oriented therapy: Emerging drugs for atopic dermatitis.Interleukin-13 Activates Distinct Cellular Pathways Leading to Ductular Reaction, Steatosis, and FibrosisMeta-analysis derived atopic dermatitis (MADAD) transcriptome defines a robust AD signature highlighting the involvement of atherosclerosis and lipid metabolism pathwaysMonoclonal antibodies: the new magic bullets for allergy: IUPHAR Review 17.The tryptophan metabolism enzyme L-kynureninase is a novel inflammatory factor in psoriasis and other inflammatory diseasesRecent considerations in the use of recombinant interferon gamma for biological therapy of atopic dermatitis.Stratum Corneum Tape Stripping: Monitoring of Inflammatory Mediators in Atopic Dermatitis Patients Using Topical Therapy.Systemic Treatment of Adult Atopic Dermatitis: A Review.Are allergic multimorbidities and IgE polysensitization associated with the persistence or re-occurrence of foetal type 2 signalling? The MeDALL hypothesis.The continuing evolution of targeted therapy for inflammatory skin disease.Dupilumab for the treatment of atopic dermatitis: A clinical trial review.Targeting key proximal drivers of type 2 inflammation in disease.Systemic Agents for Severe Atopic Dermatitis in Children.Drug evaluation review: dupilumab in atopic dermatitis.The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies.Circulating CLA+ T cells in atopic dermatitis and their possible role as peripheral biomarkers.A novel therapeutic paradigm for patients with extensive alopecia areata.The path to personalized medicine in asthma.Immunologic Targets in Atopic Dermatitis and Emerging Therapies: An Update.Blomia tropicalis-Specific TCR Transgenic Th2 Cells Induce Inducible BALT and Severe Asthma in Mice by an IL-4/IL-13-Dependent Mechanism.The Use of Omalizumab in Food Oral Immunotherapy.The anti-IL-4 receptor alpha antibody dupilumab: facing a new era in treating atopic dermatitis.Review of Systemic Treatment Options for Adult Atopic Dermatitis.Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications.Dupilumab in the treatment of moderate-to-severe atopic dermatitis.Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment.Commonality of the IL-4/IL-13 pathway in atopic diseases.Usage and effectiveness of systemic treatments in adults with severe atopic eczema: First results of the German Atopic Eczema Registry TREATgermany.Atopic dermatitis phenotypes and the need for personalized medicine.The interplay between genetic and environmental factors in the pathogenesis of atopic dermatitis.The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus.Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis.Are Biologics Efficacious in Atopic Dermatitis? A Systematic Review and Meta-Analysis.
P2860
Q26746551-E84BAC39-8F1B-4AC4-B00A-E71DFB0CF0DCQ26766224-10559FD9-ACD5-45D9-B4CA-E76F1D6E47EBQ26799532-A033BEC7-AE66-4835-B52C-75B2E0F115E4Q28396611-034498C6-476C-40AA-A03D-F2F054B28CAAQ30238648-790ABB3D-D8F2-4F6C-9E36-B3D77DBAB660Q33713754-9522DACF-8F93-44BB-A7E9-FC2403AB0896Q33890805-50DBD038-6578-4147-9646-21AB17F7B16FQ34510687-C064A817-FDC1-49D3-9728-2307DA3E26A2Q34534282-CBCF33A9-D6DD-4E88-ABBB-7A68D447EEE6Q35803992-DFFF98A7-68F3-4909-BDE4-EDD1AB044DA3Q36599623-CE9CBB3E-E9C2-4E46-8573-E29C95995B31Q36984717-347DCD5D-614A-4FD8-8E94-EFB94CE06CECQ37175410-8EBE1AD0-8B17-49C3-B1A9-0000992CABD1Q37630690-149C5130-93B1-4BCD-A567-613A9DFDE091Q37679948-0B2DE137-2A32-41F8-86EC-DDB0C2438447Q38442822-B2856138-B252-4D0C-B4C9-9AC73C506E9FQ38596134-5BB8997A-CF6C-4C5F-929C-690061D5BD3FQ38597397-5361FAD9-E8DD-4D86-9B4D-C3AF8AD9931DQ38608260-65F293C2-6113-4CE4-B88A-F7018202F1AFQ38627693-631EA41E-72EA-4094-9AA5-C90DB739A630Q38645192-358EED4F-38F8-4941-8233-A292D5CFC382Q38733182-74A7F17D-CFF1-4FC2-B0C9-FE80DAF41632Q38793743-8C45C8AC-10B5-4895-8950-9CE56EEABABDQ38831003-8C7D491B-BEB3-42F3-B7DC-8A51E3B01D76Q38843261-042DCC43-C5FE-4E30-AEA3-2DB5AF7AA0BBQ38883893-6E96D169-7638-48AA-A0B3-9872840F5CA5Q38946829-2F218433-0187-47D5-B36E-F189FF0D59FEQ38954322-2C71F8B6-40CF-4F42-AEB6-573953EA10CFQ38954461-1F6BE0F9-A1FA-43C1-A15C-73509A6CB2AAQ38956008-AE4080FB-294E-46D0-A7B9-46FACF7910B5Q39063083-BD9AD85D-49F3-49E9-81D4-A92586BCE3FEQ39122316-FE0803CB-1559-400E-96E0-9D477FAEA5FEQ39165518-BC87108A-E9D9-46A2-84D6-6479AA85A2F1Q39170851-55F03D31-5876-4BEA-A562-81B9F642142AQ39174490-FD773C81-C259-4ABB-9412-2B081FD05DF9Q39352185-C79D052A-FC46-4508-A725-4B3BB1DF4036Q39402846-84E0199F-2A09-4CD3-8718-F202E309C1A6Q47144191-E7EE0251-A4B3-405F-96B9-E742607A89EBQ47171494-6491AAF0-CB54-4A02-852F-1B2B9FF93EDFQ47664702-BAFB5E46-74B7-45C5-8B28-0D911CA94ABC
P2860
Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Dupilumab improves the molecul ...... e-to-severe atopic dermatitis.
@en
type
label
Dupilumab improves the molecul ...... e-to-severe atopic dermatitis.
@en
prefLabel
Dupilumab improves the molecul ...... e-to-severe atopic dermatitis.
@en
P2093
P1476
Dupilumab improves the molecul ...... e-to-severe atopic dermatitis.
@en
P2093
Allen R Radin
Ana Kostic
Emma Guttman-Yassky
George D Yancopoulos
Gianluca Pirozzi
Irma Cardinale
James G Krueger
Jeffrey E Ming
Jennifer D Hamilton
Mayte Suárez-Fariñas
P304
P356
10.1016/J.JACI.2014.10.013
P407
P577
2014-12-01T00:00:00Z